Intellectual Property: HHS Reference No. E-482-2013/0--U.S. Application No. 61/845,861 filed
1. Fabrication of phototriggerable liposomes.
2. Loading of a drug into the cavity and HPPH in the lipid bilayer of liposomes.
3. Laser-triggered release in vitro and in tumors.
Collaborative Research Opportunity: The
Signatures of Genetic Control in Digestive and Liver Disorders
Description of Technology: Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of-care genetic signatures is significant for both personalized biomarkers and novel targeted biotherapeutics. These microRNAs and mRNAs function either together or separately thus modulating protein expressions in one or more signaling pathways. A particular noteworthy signature of genetic control includes miR-150, which is known to modulate target proteins within the Akt signaling pathways implicated in inflammatory processes as well as processes affecting cancer cell proliferation and/or survival.
Potential Commercial Applications:
* Personalized biomarkers.
* Novel targeted biotherapeutic.
* Point-of-care signatures from minimally invasive samples.
* Protocol streamlined for high-throughput analysis.
* Quantitative molecular diagnostics.
* Unique microRNAs and/or mRNAs reveal biological targets within synergistic cellular pathways.
* In vitro data available.
* HHS Reference No. E-349-2013/0--U.S. Provisional Patent Application No. 61/825,154 filed
* HHS Reference No. E-349-2013/1--U.S. Provisional Patent Application No. 61/825,489 filed
Histone Deacteylase (HDAC) Inhibitors That Enhance Chemotherapy
Description of Technology: In cancers with KRAS-mutations, such as leukemias, colon cancer, pancreatic cancer, and lung cancer, researchers at the NCI have observed that administration of the HDAC inhibitor romidepsin in combination with certain MAPK pathway and PI3K pathway inhibitors resulted in significant cytotoxicity, regardless of the type of cancer. Further, the researchers have achieved this effect at clinically relevant dosages and time periods.
Most Popular Stories
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- 2014 World Cup Official Noisemakers Quieter than Vuvuzelas
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Dell Offers Undisclosed Number of Employee Buyouts
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Apple Activates Customer-Tracking iBeacon
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- A Biography of Jonathan Ive, Apple's Creative Chief
- Top Websites for U.S. Hispanics